Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 9/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30844292 | 1.00 | KDM1A (0.44) | KDM1AGHSRRENMAOBKDM5A | |
| SCHEMBL5402299 | 1.00 | KDM1A (0.44) | KDM1AGHSRRENMAOBKDM5A | |
| SCHEMBL29531541 | 0.95 | PRCP (0.41) | KDM1ARENMAOBKDM5AKDM1B | |
| SCHEMBL31720924 | 0.95 | PRCP (0.41) | KDM1ARENMAOBKDM5AKDM1B | |
| SCHEMBL30844263 | 0.93 | KDM1A (0.45) | KDM1AGHSRRENMAOBKDM5A | |
| SCHEMBL31544483 | 0.92 | KDM1A (0.44) | KDM1AGHSRRENMAOBKDM5A | |
| SCHEMBL30974366 | 0.92 | REN (0.46) | KDM1ARENMAOBKDM5AKDM1B | |
| SCHEMBL9120793 | 0.91 | GHSR (0.41) | KDM1AGHSRRENCPB2 | |
| SCHEMBL31385440 | 0.91 | GHSR (0.41) | KDM1AGHSRRENCPB2 | |
| SCHEMBL29588633 | 0.91 | GHSR (0.41) | KDM1AGHSRRENCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139248-A1 | DIRECT REPROGRAMMING OF HUMAN ASTROCYTES TO NEURONS WITH CRISPR-BASED TRANSCRIPTIONAL ACTIVATION | DUKE UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705462-A2 | COMPOSITIONS AND METHODS FOR ENGINEERING MATURE IPSC-DERIVED AND ESC-DERIVED HEPATOCYTES | Duke University (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705502-A1 | NANNOCHLOROPSIS-PRODUCING VIRUSES AND METHODS AND COMPOSITIONS FOR MAKING THE SAME | Insmed Incorporated (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250297035-A1 | A PEPTIDE AND THE SELECTION METHOD THEREOF | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-09-25 | — | — | US | disclosed |
| US-20250262326-A1 | EFFECTOR DOMAINS FOR CRISPR-CAS SYSTEMS | DUKE UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| EP-4590323-A2 | DIRECT REPROGRAMMING OF HUMAN ASTROCYTES TO NEURONS WITH CRISPR-BASED TRANSCRIPTIONAL ACTIVATION | Duke University (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250197823-A1 | COMPOSITIONS AND METHODS FOR EPIGENOME EDITING TO ENHANCE T CELL THERAPY | DUKE UNIVERSITY | 2025-06-19 | — | — | US | disclosed |
| EP-0656747-A1 | COMPOSITION AND METHOD FOR ALTERING DNA SEQUENCES BY HOMOLOGOUS RECOMBINATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-06-14 | — | — | EP | disclosed |
| WO-1995004064-A9 | POLYNUCLEOTIDE DECOYS THAT IHNIBIT MHC-II EXPRESSION AND USES THEREOF | — | 1995-03-09 | — | — | WO | disclosed |
| WO-1995003694-A1 | METHOD FOR MAKING UNIVERSAL DONOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1995004064-A1 | POLYNUCLEOTIDE DECOYS THAT IHNIBIT MHC-II EXPRESSION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0636028-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1995002397-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING DENDRIMER POLYCATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0626852-A1 | METHOD FOR MAKING UNIVERSAL DONOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994004032-A1 | COMPOSITION AND METHOD FOR ALTERING DNA SEQUENCES BY HOMOLOGOUS RECOMBINATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1993019768-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993014769-A1 | METHOD FOR MAKING UNIVERSAL DONOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | KDM1A 1756/4885GHSR 2584/4885REN 3824/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | KDM1A 653/4885GHSR 4787/4885REN 1010/4885 |
| US-20260139248-A1 | DIRECT REPROGRAMMING OF HUMAN ASTROCYTES TO NEURONS WITH CRISPR-BASED TRANSCRIPTIONAL ACTIVATION | NR4A2, POU2F2, NR2F2 | KDM1A 2744/4885GHSR 2062/4885REN 3591/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | KDM1A 1450/4885GHSR 2964/4885REN 998/4885 |
| US-20250262326-A1 | EFFECTOR DOMAINS FOR CRISPR-CAS SYSTEMS | CALCOCO2, ZFX, DCAF7 | KDM1A 3647/4885GHSR 3184/4885REN 2940/4885 |
| US-20250297035-A1 | A PEPTIDE AND THE SELECTION METHOD THEREOF | SPPL2B, VIP, LNPEP | KDM1A 4784/4885GHSR 1945/4885REN 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.